Fibroblast Activation Protein (FAP)-Targeted CAR-T Cells: Launching an Attack on Tumor Stroma.
Date
2021-01-01Author
Bughda, R
Dimou, P
D'Souza, RR
Klampatsa, A
Type
Journal Article
Metadata
Show full item recordAbstract
Fibroblast activation protein (FAP) is a membrane protease that is highly expressed by cancer-associated fibroblasts (CAFs). FAP can modulate the tumor microenvironment (TME) by remodeling the extracellular matrix (ECM), and its overexpression on CAFs is associated with poor prognosis in various cancers. The TME is in part accountable for the limited efficacy of chimeric antigen receptor (CAR)-T cell therapy in treatment of solid tumors. Targeting FAP with CAR-T cells is one of the strategies being researched to overcome the challenges in the TME. This review describes the role of FAP in the TME and its potential as a target in CAR-T cell immunotherapy, summarizes the preclinical studies and clinical trials of anti-FAP-CAR-T cells to date, and reviews possible optimizations to augment their cytotoxic efficiency in solid tumors.
Collections
Subject
CAR T-cells
fibroblast-activating-protein
fibroblasts
immunotherapy
solid tumors
stroma
tumor microenvironment
Research team
Thor Onco Immuno Group
Language
eng
Date accepted
2021-07-20
License start date
2021-01-01
Citation
ImmunoTargets and Therapy, 2021, 10 pp. 313 - 323
Publisher
DOVE MEDICAL PRESS LTD